Reilly Financial Advisors LLC raised its stake in Eli Lilly and Company (NYSE:LLY) by 8.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 18,857 shares of the company’s stock after buying an additional 1,530 shares during the period. Reilly Financial Advisors LLC’s holdings in Eli Lilly and were worth $1,552,000 at the end of the most recent reporting period.
Several other institutional investors have also bought and sold shares of the company. Joel Isaacson & Co. LLC increased its position in Eli Lilly and by 1.5% in the first quarter. Joel Isaacson & Co. LLC now owns 3,364 shares of the company’s stock valued at $283,000 after buying an additional 50 shares in the last quarter. Nisa Investment Advisors LLC increased its position in shares of Eli Lilly and by 3.1% in the first quarter. Nisa Investment Advisors LLC now owns 324,377 shares of the company’s stock worth $27,280,000 after buying an additional 9,680 shares during the period. Franklin Street Advisors Inc. NC purchased a new position in shares of Eli Lilly and during the first quarter worth approximately $320,000. Washington Trust Bank increased its position in shares of Eli Lilly and by 92.8% in the first quarter. Washington Trust Bank now owns 10,369 shares of the company’s stock worth $872,000 after buying an additional 4,990 shares during the period. Finally, Blair William & Co. IL increased its position in shares of Eli Lilly and by 13.1% in the first quarter. Blair William & Co. IL now owns 262,258 shares of the company’s stock worth $21,974,000 after buying an additional 30,299 shares during the period. 75.59% of the stock is currently owned by hedge funds and other institutional investors.
Eli Lilly and Company (NYSE:LLY) opened at 77.07 on Friday. Eli Lilly and Company has a 1-year low of $64.18 and a 1-year high of $86.72. The stock’s 50 day moving average is $82.39 and its 200-day moving average is $81.90. The firm has a market capitalization of $81.31 billion, a PE ratio of 33.35 and a beta of 0.34.
Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, beating analysts’ consensus estimates of $1.05 by $0.06. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The business had revenue of $5.82 billion for the quarter, compared to analysts’ expectations of $5.60 billion. During the same period in the previous year, the business earned $0.86 earnings per share. The company’s revenue was up 7.8% on a year-over-year basis. Equities research analysts forecast that Eli Lilly and Company will post $4.16 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, September 8th. Shareholders of record on Tuesday, August 15th will be given a $0.52 dividend. This represents a $2.08 annualized dividend and a yield of 2.70%. The ex-dividend date of this dividend is Friday, August 11th. Eli Lilly and’s dividend payout ratio (DPR) is presently 90.04%.
COPYRIGHT VIOLATION WARNING: This news story was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States & international copyright and trademark law. The legal version of this news story can be accessed at https://www.com-unik.info/2017/08/19/reilly-financial-advisors-llc-boosts-stake-in-eli-lilly-and-company-nyselly-updated-updated.html.
LLY has been the topic of a number of analyst reports. BMO Capital Markets set a $71.00 target price on shares of Eli Lilly and and gave the stock a “sell” rating in a research note on Tuesday, April 25th. Argus downgraded shares of Eli Lilly and from a “buy” rating to a “hold” rating and lifted their target price for the stock from $64.18 to $81.00 in a research note on Thursday, April 27th. They noted that the move was a valuation call. Jefferies Group LLC reaffirmed a “buy” rating and set a $92.00 target price (down from $94.00) on shares of Eli Lilly and in a research note on Saturday, April 29th. Goldman Sachs Group, Inc. (The) reissued a “buy” rating and issued a $92.00 price target on shares of Eli Lilly and in a research note on Tuesday, May 16th. Finally, Sanford C. Bernstein restated an “outperform” rating and issued a $88.00 price objective on shares of Eli Lilly and in a report on Sunday, May 21st. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have given a buy rating to the company. Eli Lilly and currently has a consensus rating of “Hold” and a consensus price target of $88.27.
In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 215,000 shares of the business’s stock in a transaction dated Tuesday, June 20th. The shares were sold at an average price of $83.05, for a total value of $17,855,750.00. Following the sale, the insider now directly owns 124,475,804 shares in the company, valued at $10,337,715,522.20. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Michael J. Harrington sold 22,833 shares of the business’s stock in a transaction dated Friday, June 9th. The stock was sold at an average price of $79.97, for a total transaction of $1,825,955.01. Following the completion of the sale, the vice president now owns 62,056 shares in the company, valued at $4,962,618.32. The disclosure for this sale can be found here. Over the last quarter, insiders sold 669,733 shares of company stock worth $55,845,287. 0.20% of the stock is owned by company insiders.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
What are top analysts saying about Eli Lilly and Company? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Eli Lilly and Company and related companies.